Infinity Pharmaceuticals | INFI - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.81B 13.45B 2025-12
Alterity Therapeutics Limited AUD 7.78M 3M 2023-06
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 9.78M 90K 2025-09
CSL USD 5.7B 2.82B 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Grifols EUR 1.77B 22.04M 2025-09
Incyte USD 1.12B 3.53B 2025-12
Infinity Pharmaceuticals USD 10.7M 1.54M 2023-06
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Novartis USD 9.86B 115M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12